MAO‐B inhibitors for the treatment of Parkinson's disease
Identifieur interne : 004396 ( Main/Exploration ); précédent : 004395; suivant : 004397MAO‐B inhibitors for the treatment of Parkinson's disease
Auteurs :Source :
- Movement Disorders [ 0885-3185 ] ; 2002-07.
English descriptors
- KwdEn :
- Humans, Monoamine Oxidase (metabolism), Monoamine Oxidase Inhibitors (adverse effects), Monoamine Oxidase Inhibitors (pharmacology), Monoamine Oxidase Inhibitors (therapeutic use), Parkinson Disease (drug therapy), Randomized Controlled Trials as Topic, Selegiline (adverse effects), Selegiline (pharmacology), Selegiline (therapeutic use).
- MESH :
- chemical , adverse effects : Monoamine Oxidase Inhibitors, Selegiline.
- chemical , metabolism : Monoamine Oxidase.
- chemical , pharmacology : Monoamine Oxidase Inhibitors, Selegiline.
- chemical , therapeutic use : Monoamine Oxidase Inhibitors, Selegiline.
- drug therapy : Parkinson Disease.
- Humans, Randomized Controlled Trials as Topic.
Url:
DOI: 10.1002/mds.5559
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001D16
- to stream Istex, to step Curation: 001D16
- to stream Istex, to step Checkpoint: 002C87
- to stream PubMed, to step Corpus: 003986
- to stream PubMed, to step Curation: 003986
- to stream PubMed, to step Checkpoint: 003A32
- to stream Ncbi, to step Merge: 000865
- to stream Ncbi, to step Curation: 000865
- to stream Ncbi, to step Checkpoint: 000865
- to stream Main, to step Merge: 006401
- to stream Main, to step Curation: 004396
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">MAO‐B inhibitors for the treatment of Parkinson's disease</title>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:38BE27635785C49F0C30D9E243F8AB2DD44D0577</idno>
<date when="2002" year="2002">2002</date>
<idno type="doi">10.1002/mds.5559</idno>
<idno type="url">https://api.istex.fr/document/38BE27635785C49F0C30D9E243F8AB2DD44D0577/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001D16</idno>
<idno type="wicri:Area/Istex/Curation">001D16</idno>
<idno type="wicri:Area/Istex/Checkpoint">002C87</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:12211138</idno>
<idno type="wicri:Area/PubMed/Corpus">003986</idno>
<idno type="wicri:Area/PubMed/Curation">003986</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003A32</idno>
<idno type="wicri:Area/Ncbi/Merge">000865</idno>
<idno type="wicri:Area/Ncbi/Curation">000865</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000865</idno>
<idno type="wicri:Area/Main/Merge">006401</idno>
<idno type="wicri:Area/Main/Curation">004396</idno>
<idno type="wicri:Area/Main/Exploration">004396</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">MAO‐B inhibitors for the treatment of Parkinson's disease</title>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="2002-07">2002-07</date>
<biblScope unit="vol">17</biblScope>
<biblScope unit="issue">S4</biblScope>
<biblScope unit="supplement">4</biblScope>
<biblScope unit="page" from="S38">S38</biblScope>
<biblScope unit="page" to="S44">S44</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">38BE27635785C49F0C30D9E243F8AB2DD44D0577</idno>
<idno type="DOI">10.1002/mds.5559</idno>
<idno type="ArticleID">MDS5559</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Humans</term>
<term>Monoamine Oxidase (metabolism)</term>
<term>Monoamine Oxidase Inhibitors (adverse effects)</term>
<term>Monoamine Oxidase Inhibitors (pharmacology)</term>
<term>Monoamine Oxidase Inhibitors (therapeutic use)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Randomized Controlled Trials as Topic</term>
<term>Selegiline (adverse effects)</term>
<term>Selegiline (pharmacology)</term>
<term>Selegiline (therapeutic use)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Monoamine Oxidase Inhibitors</term>
<term>Selegiline</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Monoamine Oxidase</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Monoamine Oxidase Inhibitors</term>
<term>Selegiline</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Monoamine Oxidase Inhibitors</term>
<term>Selegiline</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
<term>Randomized Controlled Trials as Topic</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
</TEI>
<affiliations><list></list>
<tree></tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004396 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004396 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:38BE27635785C49F0C30D9E243F8AB2DD44D0577 |texte= MAO‐B inhibitors for the treatment of Parkinson's disease }}
![]() | This area was generated with Dilib version V0.6.23. | ![]() |